An ileal neobladder or augmentation is used when the native bladder is surgically removed, functionally incompetent, or embryologically absent. In Australia, neobladder reconstruction for cancer-related cystectomy accounts for approximately 8% of cases, compared to 22–39% in some international studies. The reported incidence of calculi formation in neobladders is 0.3%, though in some studies it can range from 11% to 27% depending on the type of neobladder. This is influenced by risk factors such as metabolic acidosis, urinary stasis, mucus production, and recurrent infections.

Without long-term follow-up, neobladder stones can grow to significant sizes and present a considerable surgical challenge.

Historically, this has been managed with open cystolithotomy, often published as case reports. However, complications such as wound infection and dehiscence are well-documented, with recurrence rates as high as 63% within 3–5 years of the initial procedure. We outline the technique of percutaneous stone treatment utilizing a dual-energy single-probe suction lithotripter to minimize complications in this patient cohort.